SCM
PTLA

Silvant Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Silvant Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,686
Closed -$215K – 350
2018
Q2 		$215K Hold
5,686
– – 0.03% 190
2018
Q1 		$186K Buy
+5,686
New +$250K 0.02% 206

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Silvant Capital Management's PTLA Position: Q3 2018 in Review

Silvant Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2018, closing a stake of 5,686 shares — an estimated $215K sold.

Silvant Capital Management first reported a position in PTLA in Q1 2018 and held it in 2 quarters. The position peaked at $215K in Q2 2018. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

  • Silvant Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Silvant Capital Management sold 5,686 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $215K.
  • Silvant Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • Silvant Capital Management's Portola Pharmaceuticals, Inc. position peaked at $215K in Q2 2018.
  • 197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Silvant Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.